Top

Journal of Cardiovascular Translational Research

Published in:

01-02-2014

Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial

Authors: Marco Valgimigli, Paolo Calabrò, Bernardo Cortese, Enrico Frigoli, Stefano Garducci, Paolo Rubartelli, Giuseppe Andò, Andrea Santarelli, Mario Galli, Roberto Garbo, Alessandra Repetto, Salvatore Ierna, Carlo Briguori, Ugo Limbruno, Roberto Violini, Andrea Gagnor, on behalf of the MATRIX investigators

Published in: Journal of Cardiovascular Translational Research | Issue 1/2014

Abstract

Early invasive management and the use of combined antithrombotic therapies have decreased the risk of recurrent ischaemia in patients with acute coronary syndrome (ACS) but have also increased the bleeding risk. Transradial intervention (TRI) and bivalirudin infusion compared to transfemoral intervention (TFI) or unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decrease bleeding complications in patients with ACS. To what extent, a bleeding preventive strategy incorporating at least one of these two treatment options translates into improved outcomes is a matter of debate. The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX study is a large-scale, multicenter, prospective, open-label trial, conducted at approximately 100 sites in Europe aiming to primarily assess whether TRI and bivalirudin infusion, as compared to TFI and UFH plus provisional GPI, decrease the 30-day incidence of death, myocardial infarction or stroke across the whole spectrum of ACS patients.

Steg, P. G., James, S. K., Atar, D., et al. (2012). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33, 2569–2619.PubMedCrossRef

Jneid, H., Anderson, J. L., Wright, R. S., et al. (2012). 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 126, 875–910.PubMedCrossRef

Doyle, B. J., Rihal, C. S., Gastineau, D. A., & Holmes, D. R., Jr. (2009). Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. Journal of the American College of Cardiology, 53, 2019–2027.PubMedCrossRef

Rao, S. V., O’Grady, K., Pieper, K. S., et al. (2005). Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. The American Journal of Cardiology, 96, 1200–1206.PubMedCrossRef

Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A., & Yusuf, S. (2006). Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114, 774–782.PubMedCrossRef

Hochholzer, W., Wiviott, S. D., Antman, E. M., et al. (2011). Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation, 123, 2681–2689.PubMedCrossRef

Spencer, F. A., Moscucci, M., Granger, C. B., et al. (2007). Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation, 116, 2793–2801.PubMedCrossRef

Wang, T. Y., Xiao, L., Alexander, K. P., et al. (2008). Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation, 118, 2139–2145.PubMedCrossRef

Rao, S. V., Jollis, J. G., Harrington, R. A., et al. (2004). Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. Jama, 292, 1555–1562.PubMedCrossRef

10.

Sabatine, M. S., Morrow, D. A., Giugliano, R. P., et al. (2005). Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation, 111, 2042–2049.PubMedCrossRef

11.

Lopes, R. D., Subherwal, S., Holmes, D. N., et al. (2012). The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. European Heart Journal, 33, 2044–2053.PubMedCrossRef

12.

Yusuf, S., Mehta, S. R., Chrolavicius, S., et al. (2006). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The New England Journal of Medicine, 354, 1464–1476.PubMedCrossRef

13.

Stone, G. W., Witzenbichler, B., Guagliumi, G., et al. (2008). Bivalirudin during primary PCI in acute myocardial infarction. The New England Journal of Medicine, 358, 2218–2230.PubMedCrossRef

14.

Dewilde, W. J., Oirbans, T., Verheugt, F. W., et al. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 381, 1107–1115.PubMedCrossRef

15.

Cutlip, D. E., Windecker, S., Mehran, R., et al. (2007). Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 115, 2344–2351.PubMedCrossRef

16.

Mehran, R., Rao, S. V., Bhatt, D. L., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 123, 2736–2747.PubMedCrossRef

17.

Ndrepepa, G., Schuster, T., Hadamitzky, M., et al. (2012). Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation, 125, 1424–1431.PubMedCrossRef

18.

Valgimigli, M., Campo, G., Percoco, G., et al. (2010). Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal, 160, 804–811.PubMedCrossRef

19.

Stone, G. W., McLaurin, B. T., Cox, D. A., et al. (2006). Bivalirudin for patients with acute coronary syndromes. The New England Journal of Medicine, 355, 2203–2216.PubMedCrossRef

20.

Montalescot, G., White, H. D., Gallo, R., et al. (2006). Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. The New England Journal of Medicine, 355, 1006–1017.PubMedCrossRef

21.

White, H. D., Aylward, P. E., Gallo, R., et al. (2010). Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. American Heart Journal, 159, 110–116.PubMedCrossRef

22.

Vranckx, P., Campo, G., Anselmi, M., et al. (2012). Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. EuroIntervention, 8, 71–78.PubMedCrossRef

23.

Verheugt, F. W., Steinhubl, S. R., Hamon, M., et al. (2011). Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. Journal of the American Chemical Society, 4, 191–197.

24.

Campeau, L. (1989). Percutaneous radial artery approach for coronary angiography. Catheterization and Cardiovascular Diagnosis, 16, 3–7.PubMedCrossRef

25.

Valgimigli, M., Saia, F., Guastaroba, P., et al. (2012). Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell’Emilia-Romagna) multicenter registry. Journal of the American Chemical Society, 5, 23–35.

26.

Jolly, S. S., Yusuf, S., Cairns, J., et al. (2011). Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, 377, 1409–1420.PubMedCrossRef

27.

Romagnoli, E., Biondi-Zoccai, G., Sciahbasi, A., et al. (2012). Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. Journal of the American College of Cardiology, 60, 2481–2489.PubMedCrossRef

28.

Parodi, G., Antoniucci, D., Nikolsky, E., et al. (2010). Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. Journal of the American Chemical Society, 3, 796–802.

29.

Steg, P. G., van’t Hof, A., Hamm, C. W., et al. (2013). Bivalirudin started during emergency transport for primary PCI. The New England Journal of Medicine, 369, 2207–2217.PubMedCrossRef

30.

Valgimigli, M., Tebaldi, M., Campo, G., et al. (2012). Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. Journal of the American Chemical Society, 5, 268–277.

31.

Cortese, B., Limbruno, U., Severi, S., De Matteis, S., Diehl, L., & Piti, A. (2011). Effect of prolonged Bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study). The American Journal of Cardiology, 108, 1220–1224.PubMedCrossRef

32.

Cortese, B., Picchi, A., Micheli, A., et al. (2009). Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris. The American Journal of Cardiology, 104, 1063–1068.PubMedCrossRef

33.

Stone, G. W. (2009). Ischaemia versus bleeding: the art of clinical decision-making. Lancet, 373, 695–696.PubMedCrossRef

34.

Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival). Lancet, 2, 349–360.

35.

The GUSTO investigators. (1993). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The New England Journal of Medicine, 329, 673–682.CrossRef

36.

Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 361, 13–20.PubMedCrossRef

Title: Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial
Authors: Marco Valgimigli
Paolo Calabrò
Bernardo Cortese
Enrico Frigoli
Stefano Garducci
Paolo Rubartelli
Giuseppe Andò
Andrea Santarelli
Mario Galli
Roberto Garbo
Alessandra Repetto
Salvatore Ierna
Carlo Briguori
Ugo Limbruno
Roberto Violini
Andrea Gagnor
on behalf of the MATRIX investigators
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 1/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9537-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside

Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications

Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

Non Optical Semi-Conductor Next Generation Sequencing of the Main Cardiac QT-Interval Duration Genes in Pooled DNA Samples

Antiplatelet Therapy: Targeting the TxA2 Pathway